Physician profile
Douglas H Jones
NPI 1346324761
$556,734.45
in general payments reported to CMS, 2019-2025
30 companies · $85K in 2025
The $85K reported for 2025 was more than what 97% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76K · 2020: $102K · 2021: $66K · 2022: $76K · 2023: $50K · 2024: $102K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $101K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $87K · Travel and Lodging: $29K · Food and Beverage: $11K · Honoraria: $7,496 · Education: $37.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $101,371.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,107.00 |
| Travel and Lodging | $29,397.84 |
| Food and Beverage | $11,352.64 |
| Honoraria | $7,496.00 |
| Education | $37.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $190,668.81 | 2019-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $154,644.61 | 2020-2025 | Takhzyro, Cinryze, Eohilia |
| Shire North American Group INC | $43,940.07 | 2019 | |
| Genentech USA, INC. | $42,009.92 | 2023-2025 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $31,883.68 | 2019-2024 | Tezspire, Fasenra, Airsupra |
| Csl Behring | $30,636.99 | 2019-2025 | Andembry, Haegarda, Hizentra |
| Ionis Pharmaceuticals, INC. | $15,161.59 | 2025 | Dawnzera |
| Regeneron Healthcare Solutions, INC. | $9,831.38 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $9,220.13 | 2021-2025 | Orladeyo |
| Blueprint Medicines Corporation | $7,956.01 | 2022-2024 | Ayvakit |
| Biocryst Pharmaceuticals, INC. | $5,642.62 | 2019-2025 | Orladeyo |
| Cycle Pharmaceuticals INC | $4,007.36 | 2022-2025 | Sajazir |
| Genentech, INC. | $3,913.14 | 2023-2024 | Xolair |
| Genzyme Corporation | $3,761.02 | 2019-2025 | |
| Amgen INC. | $1,917.15 | 2022-2024 | Tezspire |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $500.00 | 2023 | Ragwitek, Odactra, Grastek |
| Novartis Pharmaceuticals Corporation | $165.38 | 2019-2025 | |
| Grifols USA, LLC | $144.41 | 2019-2024 | Xembify, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $128.19 | 2023-2025 | Nucala |
| Kaleo, INC. | $119.93 | 2019-2024 | Auvi-Q |
| Regeneron Pharmaceuticals, INC. | $107.41 | 2022 | |
| Pfizer INC. | $89.71 | 2019-2023 | |
| Bio Products Laboratory USA, INC. | $65.01 | 2022-2023 | Gammaplex, Coagadex |
| Teva Pharmaceuticals USA, INC. | $63.05 | 2019-2022 | |
| Leo Pharma INC. | $46.38 | 2023-2025 | Adbry |
| Octapharma USA, INC. | $28.49 | 2022 | |
| Mylan Specialty L.P. | $26.13 | 2024 | Yupelri |
| Sanofi Pasteur INC. | $24.23 | 2023 | |
| Sunovion Pharmaceuticals INC. | $16.11 | 2019 | |
| Circassia INC. | $15.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.